MLR-1023 is a potent and selective allosteric activator of Lyn kinase in vitro that improves glucose tolerance in vivo

Journal of Pharmacology and Experimental Therapeutics

Volumn 342, Issue 1, 2012, Pages 15-22

  Saporito, Michael S ^a   Ochman, Alexander R ^a   Lipinski, Christopher A ^b   Handler, Jeffrey A ^c   Reaume, Andrew G ^a  

^a Melior Discovery Inc   (United States)

^b Melior Discovery Inc   (United States)

^c JAH Associates LLC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 [4 [3 (4 ACETYL 3 HYDROXY 2 PROPYLPHENOXY)PROPOXY]PHENOXY]ACETIC ACID; ADENOSINE TRIPHOSPHATE; ADIPONECTIN; ALPHA GLUCOSIDASE; ANTIDIABETIC AGENT; BEZAFIBRATE; CASTANOSPERMINE; DIPEPTIDYL PEPTIDASE IV; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLUCOSE; INSULIN; ISOLEUCINE THIAZOLIDIDE; METFORMIN; MLR 1023; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROTEIN KINASE LYN; ROSIGLITAZONE; TOLIMIDONE; UNCLASSIFIED DRUG;

ADIPOCYTE; ALLOSTERISM; ANIMAL CELL; ANIMAL EXPERIMENT; ANTIDIABETIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG STRUCTURE; ENZYME ACTIVATION; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE; IN VITRO STUDY; IN VIVO STUDY; INSULIN RELEASE; MALE; MAXIMUM PLASMA CONCENTRATION; MOUSE; NONHUMAN; ORAL GLUCOSE TOLERANCE TEST; PRIORITY JOURNAL; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADENOSINE TRIPHOSPHATE; ALLOSTERIC REGULATION; ALPHA-GLUCOSIDASES; ANIMALS; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL PEPTIDASE 4; GLUCOSE TOLERANCE TEST; HYPOGLYCEMIC AGENTS; INSULIN; MALE; MICE; MICE, INBRED ICR; MICE, KNOCKOUT; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS; PROTEIN KINASE INHIBITORS; PYRIMIDINONES; RECEPTORS, GLUCAGON; SIGNAL TRANSDUCTION; SRC-FAMILY KINASES;

EID: 84862503641     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.112.192096     Document Type: Article

References (40)

1. Carmona MC, Louche K, Lefebvre B, Pilon A, Hennuyer N, Audinot-Bouchez V, Fievet C, Torpier G, Formstecher P, Renard P, et al. (2007) S 26948: a new specific peroxisome proliferator activated receptor γ modulator with potent antidiabetes and antiatherogenic effects. Diabetes 56:2797-2808. (Pubitemid 350044924)
2. Chan VW, Meng F, Soriano P, DeFranco AL, and Lowell CA (1997) Characterization of the B lymphocyte populations in Lyn-deficient mice and the role of Lyn in signal initiation and down-regulation. Immunity 7:69-81. (Pubitemid 27357266)
3. Cool B, Zinker B, Chiou W, Kifle L, Cao N, Perham M, Dickinson R, Adler A, Gagne G, Iyengar R, et al. (2006) Identification and characterization of a small molecule AMPK activator that treats key components of type 2 diabetes and the metabolic syndrome. Cell Metab 3:403-416. (Pubitemid 43811782)
4. DeFronzo RA (2010) Current issues in the treatment of type 2 diabetes. Overview of newer agents: where treatment is going. Am J Med 123:S38-S48.
5. Donella-Deana A, Cesaro L, Ruzzene M, Brunati AM, Marin O, and Pinna LA (1998) Spontaneous autophosphorylation of Lyn tyrosine kinase at both its activation segment and C-terminal tail confers altered substrate specificity. Biochemistry 37:1438-1446. (Pubitemid 28135734)
6. Eglen R and Reisine T (2011) Drug discovery and the human kinome: recent trends. Pharmacol Ther 130:144-156.
7. Gervois P, Torra IP, Chinetti G, Grötzinger T, Dubois G, Fruchart JC, Fruchart-Najib J, Leitersdorf E, and Staels B (1999) A truncated human peroxisome proliferator-activated receptor α splice variant with dominant negative activity. Mol Endocrinol 13:1535-1549. (Pubitemid 30650594)
8. Gibb SL, Jeanblanc J, Barak S, Yowell QV, Yaka R, and Ron D (2011) Lyn kinase regulates mesolimbic dopamine release: implication for alcohol reward. J Neurosci 31:2180-2187.
9. Göransson O, McBride A, Hawley SA, Ross FA, Shpiro N, Foretz M, Viollet B, Hardie DG, and Sakamoto K (2007) Mechanism of action of A-769662, a valuable tool for activation of AMP-activated protein kinase. J Biol Chem 282:32549-32560. (Pubitemid 350159310)
10. Ingley E (2008) Src family kinases: regulation of their activities, levels and identification of new pathways. Biochim Biophys Acta 1784:56-65.
11. Institute of Laboratory Animal Resources (1996) Guide for the Care and Use of Laboratory Animals 7th ed. Institute of Laboratory Animal Resources, Commission on Life Sciences, National Research Council, Washington, DC.
12. Jehle PM, Jehle D, Fussgänger RD, and Adler G (1995) Effects of glucagon-like peptide-1 (GLP-1) in RINm5F insulinoma cells. Stimulation of insulin secretion, insulin content, and insulin receptor binding. Exp Clin Endocrinol Diabetes 103 (Suppl 2):31-36.
13. Kieffer TJ, McIntosh CH, and Pederson RA (1995) Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV. Endocrinology 136:3585-3596.
14. Krentz AJ and Bailey CJ (2005) Oral antidiabetic agents: current role in type 2 diabetes mellitus. Drugs 65:385-411. (Pubitemid 40227460)
15. Lebrun P, Mothe-Satney I, Delahaye L, Van Obberghen E, and Baron V (1998) Insulin receptor substrate-1 as a signaling molecule for focal adhesion kinase pp125(FAK) and pp60(src). J Biol Chem 273:32244-32253. (Pubitemid 29177171)
16. Li D, Kang Q, and Wang DM (2007) Constitutive coactivator of peroxisome proliferator-activated receptor (PPARγ), a novel coactivator of PPARγ that promotes adipogenesis. Mol Endocrinol 21:2320-2333. (Pubitemid 47529348)
17. Lipinski CA, Stam JG, Pereira JN, Ackerman NR, and Hess HJ (1980) Bronchodilator and antiulcer phenoxypyrimidinones. J Med Chem 23:1026-1031. (Pubitemid 11170636)
18. Müller G (2000) The molecular mechanism of the insulin-mimetic/ sensitizing activity of the antidiabetic sulfonylurea drug Amaryl. Mol Med 6:907-933.
19. Müller G, Jung C, Wied S, Welte S, and Frick W (2001a) Insulin-mimetic signaling by the sulfonylurea glimepiride and phosphoinositolglycans involves distinct mechanisms for redistribution of lipid raft components. Biochemistry 40:14603-14620. (Pubitemid 33111744)
20. Müller G, Jung C, Wied S, Welte S, Jordan H, and Frick W (2001b) Redistribution of glycolipid raft domain components induces insulin-mimetic signaling in rat adipocytes. Mol Cell Biol 21:4553-4567. (Pubitemid 32588239)
21. Müller G, Schulz A, Wied S, and Frick W (2005) Regulation of lipid raft proteins by glimepiride- and insulin-induced glycosylphosphatidylinositol- specific phospholipase C in rat adipocytes. Biochem Pharmacol 69:761-780. (Pubitemid 40248619)
22. Mügller G, Wied S, and Frick W (2000) Cross talk of pp125(FAK) and pp59(Lyn) non-receptor tyrosine kinases to insulin-mimetic signaling in adipocytes. Mol Cell Biol 20:4708-4723. (Pubitemid 30396118)
23. Ochman AR, Lipinski CA, Handler JA, Reaume AG, and Saporito MS (2012) The Lyn kinase activator MLR-1023 is a novel insulin receptor potentiator that elicits a rapid-onset and durable improvement in glucose homeostasis in animal models of type 2 diabetes. J Pharmacol Exp Ther 342:23-32.
24. Pang T, Zhang ZS, Gu M, Qiu BY, Yu LF, Cao PR, Shao W, Su MB, Li JY, Nan FJ, et al. (2008) Small molecule antagonizes autoinhibition and activates AMP-activated protein kinase in cells. J Biol Chem 283:16051-16060.
25. Pertel T, Zhu D, Panettieri RA, Yamaguchi N, Emala CW, and Hirshman CA (2006) Expression and muscarinic receptor coupling of Lyn kinase in cultured human airway smooth muscle cells. Am J Physiol Lung Cell Mol Physiol 290:L492-L500. (Pubitemid 43725094)
26. Raspé E, Madsen L, Lefebvre AM, Leitersdorf I, Gelman L, Peinado-Onsurbe J, Dallongeville J, Fruchart JC, Berge R, and Staels B (1999) Modulation of rat liver apolipoprotein gene expression and serum lipid levels by tetradecylthioacetic acid (TTA) via PPARα activation. J Lipid Res 40:2099-2110. (Pubitemid 29523436)
27. Ridruejo JC, Muñoz MD, Andaluz E, and Larriba G (1989) Inhibition of yeast exoglucanases by glucosidase inhibitors. Biochim Biophys Acta 993:179-185. (Pubitemid 20004634)
28. Salituro GM, Pelaez F, and Zhang BB (2001) Discovery of a small molecule insulin receptor activator. Recent Prog Horm Res 56:107-126.
29. Sanders MJ, Ali ZS, Hegarty BD, Heath R, Snowden MA, and Carling D (2007) Defining the mechanism of activation of AMP-activated protein kinase by the small molecule A-769662, a member of the thienopyridone family. J Biol Chem 282:32539-32548. (Pubitemid 350159309)
30. Saporito MS, Lipinski CA and Reaume A (2012) Phenotypic in vivo screening to identify new, unpredicted indications for existing drugs and drug candidates, in Drug Repositioning: Bringing New Life to Shelved Assets (Barratt MJ and Frail D eds) pp 253-280, John Wiley & Sons, Hoboken, NJ.
31. Scapini P, Pereira S, Zhang H, and Lowell CA (2009) Multiple roles of Lyn kinase in myeloid cell signaling and function. Immunol Rev 228:23-40.
32. Simpson GL, Hughes JA, Washio Y, and Bertrand SM (2009) Direct small-molecule kinase activation: novel approaches for a new era of drug discovery. Curr Opin Drug Discov Devel 12:585-596.
33. Staels B, Koenig W, Habib A, Merval R, Lebret M, Torra IP, Delerive P, Fadel A, Chinetti G, Fruchart JC, et al. (1998) Activation of human aortic smooth-muscle cells is inhibited by PPARα but not by PPARγ activators. Nature 393:790-793. (Pubitemid 28299490)
34. Tahrani AA, Bailey CJ, Del Prato S, and Barnett AH (2011) Management of type 2 diabetes: new and future developments in treatment. Lancet 378:182-197.
35. Tamori Y, Masugi J, Nishino N, and Kasuga M (2002) Role of peroxisome proliferator-activated receptor-γ in maintenance of the characteristics of mature 3T3-L1 adipocytes. Diabetes 51:2045-2055. (Pubitemid 34729007)
36. Viollet B, Mounier R, Leclerc J, Yazigi A, Foretz M, and Andreelli F (2007) Targeting AMP-activated protein kinase as a novel therapeutic approach for the treatment of metabolic disorders. Diabetes Metab 33:395-402. (Pubitemid 350218220)
37. Watanabe Y, Kawai K, Ohashi S, Yokota C, Suzuki S, and Yamashita K (1994) Structure-activity relationships of glucagon-like peptide-1(7-36)amide: insulinotropic activities in perfused rat pancreases, and receptor binding and cyclic AMP production in RINm5F cells. J Endocrinol 140:45-52. (Pubitemid 24115302)
38. Xu A, Wong LC, Wang Y, Xu JY, Cooper GJ, and Lam KS (2004) Chronic treatment with growth hormone stimulates adiponectin gene expression in 3T3-L1 adipocytes. FEBS Lett 572:129-134. (Pubitemid 39092524)
39. Yamada E, Pessin JE, Kurland IJ, Schwartz GJ, and Bastie CC (2010) Fyn-dependent regulation of energy expenditure and body weight is mediated by tyrosine phosphorylation of LKB1. Cell Metab 11:113-124.
40. Zhang B, Salituro G, Szalkowski D, Li Z, Zhang Y, Royo I, Vilella D, Díez MT, Pelaez F, Ruby C, et al. (1999) Discovery of a small molecule insulin mimetic with antidiabetic activity in mice. Science 284:974-977. (Pubitemid 29288438)